Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Biotechnology & Medical Research

Applied Genetic Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended June 30, 2021

September 23, 2021 at 04:14 pm EDT

Applied Genetic Technologies Corporation announced earnings results for the fourth quarter ended June 30, 2021. For the fourth quarter, the company announced total revenue was USD 500,000. Operating loss was USD 13.786 million compared to USD 14.580 million a year ago. Net loss was USD 12.136 million compared to USD 14.503 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.56 a year ago. For the full year, total revenue was USD 500,000 compared to USD 2.453 million a year ago. Operating loss was USD 58.451 million compared to USD 46.942 million a year ago. Net loss was USD 57.829 million compared to USD 45.892 million a year ago. Basic loss per share from continuing operations was USD 1.77 compared to USD 2.17 a year ago.

Latest news about Applied Genetic Technologies Corporation

Syncona's Achilles says cancer treatment shows promise; seals buy	22-12-01	AN
British Investor Syncona Closes Acquisition of US Biotech Applied Genetic Technologies	22-12-01	MT
Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index	22-12-01	CI
Syncona Limited, a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation.	22-11-29	CI
Applied Genetic Technologies Says Syncona Extends Tender Offer Through Wednesday	22-11-29	MT
TOP NEWS: AstraZeneca to buy Neogene for cancer treatment	22-11-29	AN
Syncona Extends Offer Period For $24 Million Takeover of Applied Genetic Technologies	22-11-29	MT
Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from S&P TMI Index	22-11-29	CI
North American Morning Briefing : Stock Gains Seen -2-	22-11-22	DJ
Applied Genetic Technologies Corporation Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-21	CI
North American Morning Briefing : Positive China -2-	22-11-15	DJ
Wells Fargo Trims Applied Genetic Technologies' Price Target to $0.40 From $0.50, Keeps Equalweight Rating	22-10-25	MT
HC Wainwright Downgrades Applied Genetic Technologies to Neutral From Buy	22-10-25	MT
Chardan Research Downgrades Applied Genetic Technologies to Neutral From Buy, Adjusts Price Target to $0.34 From $3	22-10-25	MT
Sector Update: Health Care Stocks Pacing Monday Markets as Defensive Sectors Shine	22-10-24	MT
Sector Update: Health Care Stocks Pacing Monday Markets Advance	22-10-24	MT
Applied Genetic Technologies Shares Soar After Company Agrees to Sell to Syncona for $23.5 Million	22-10-24	MT
Stifel Nicolaus Downgrades Applied Genetic Technologies to Hold From Buy, Adjusts Price Target to $0.34 From $3	22-10-24	MT
Wall Street Set to Open Higher as Markets Look to Build on Strong Week Ahead of PMI Data	22-10-24	MT
ETF Preview: ETFs, Futures Rising Pre-Bell After Chicago Fed National Activity Index Report	22-10-24	MT
Wedbush Downgrades Applied Genetic Technologies to Neutral From Outperform, Adjusts Price Target to $0.34 From $2 on Syncona Tender Offer	22-10-24	MT
US Futures Higher, Looking to Build on Strong Week Ahead of PMI Data	22-10-24	MT
Top Premarket Gainers	22-10-24	MT
Transcript : Applied Genetic Technologies Corporation, Syncona Limited - M&A Call	22-10-24
Applied Genetic Technologies Agrees to Sell to Syncona for $23.5 Million Through Tender Offer	22-10-24	MT

Chart Applied Genetic Technologies Corporation

Duration

Period

Chart Applied Genetic Technologies Corporation

More charts

Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). It has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.26%	103B
REGENERON PHARMACEUTICALS, INC.	+3.71%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.18%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-23.18%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.69%	13.44B
SAREPTA THERAPEUTICS, INC.	+22.09%	10.98B

Bio Therapeutic Drugs